Skip to main content
Premium Trial:

Request an Annual Quote

Revenues Up, Earnings Down at Applied Biosystems in Q4

This story has been updated from a previous version. Click here to read the updated story.


NEW YORK, July 28 (GenomeWeb News) - Applied Biosystems today reported a significant drop in earnings amid increasing revenues for the fourth quarter of fiscal 2004.


ABI said that its net earnings for Q4 2004 were $51.1 million, or $.20 per share, versus $96.1 million, or $.46 per share in Q4 2003. Net income for the entire fiscal 2004 was $182.9 million, a slight dip from the $183.2 million reported for fiscal 2003.


Net revenues in the fourth quarter were $460.5 million, a six-percent increase over the $432.9 million reported in the same period last year. ABI said that Q4 2004 instrument revenues increased seven percent, to $231.2 million, and consumables revenues increased three percent to $153 million. In addition, revenues from other sources, such as service and support, royalties, licenses, and consulting increased 12 percent to $76.3 million.


R&D spending took a light hit, falling to $56.4 million in Q4 2004 from $58.2 million for the same quarter last year.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.